

Eculizumab; 依库珠单抗

产品编号: MB2023

质量标准: >95%, 蛋白原液

包装规格: 1MG/5MG

产品形式:

基本信息

分子量	148KD
CAS NO	219685-50-4
储存条件	-70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light

简介: Eculizumab is a recombinant human IgG2/4k monoclonal antibody used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Eculizumab acts as a terminal complement inhibitor that binds to the terminal complement component 5, or C5 and suppresses the complement cascade.

产品形式: 蛋白原液。每种装于冻存管中，单抗质量为标示数量 1MG 或者 5MG，体积根据其浓度不同略有不同。

质量标准:

Non-reduced CE-SDS:.....>90%;

SEC-HPLC:.....>95%;

Bacterial Endotoxins Test: <10EU/ml

Residual Proteins of HostCell: <100 ng/mg

Exogenous residual DNA: <100pg/mg

Residual Protein A: <100 ng/mg

Biological Activity:..... 80% to 125% of standard

储存条件: -70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light.

使用建议:

meilunbio 提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量 1MG 或者 5MG，体积根据其浓度不同略有不同。

使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(meilunbio 货号 MA0028，去离子无菌水(细胞培养用水))或者 PBS (meilunbio 货号 MA0015PBS(1X),细胞培养级)。

不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。

稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，

举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml

对应 5MG 包装的蛋白原液体积为 5mg (质量) /50mg/ml(浓度)=0.1ML，

实验需求蛋白浓度为 10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入 0.4ML,即 400ul PBS 或者无菌去离子水即可。

若给药量为固定质量值, 比如单次给药 0.5MG, 对应蛋白原液给药体积为 10ul, 建议稀释后, 提高给药体积降低误差, 因为注射器或者移液器吸头残留会影响实验效果。

稀释后的蛋白溶液, 可于 2-8 度冷藏避光保存不超过 2 周, 不建议长期储存。

避免反复冻融, 每次冻融蛋白活性会降低约 5%左右。

生物活性 (仅来自于公开文献, 不保证其有效性)

描述	Eculizumab is a recombinant human IgG2/4k monoclonal antibody used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Eculizumab acts as a terminal complement inhibitor that binds to the terminal complement component 5, or C5 and suppresses the complement cascade.
靶点	补体蛋白(C5)
Application	the treatment of PNH and aHUS.
体内	<p>A human FcRn (hFcRn) transgenic mouse strain was used to model the PK and PD of surrogate anti-mouse C5 antibodies with eculizumab-derived Fc domains. Preliminary studies showed that the chimeric murine-human antibodies elicited a high frequency of anti-drug antibodies in this mouse strain; therefore, animals were immune-suppressed with a murine anti-CD4 antibody administered in a 500 µg intraperitoneal loading dose at day -3 and weekly maintenance doses of 100 µg. Test articles were administered in a single 1000 µg IV dose on study day 0. Approximately 100 µL of blood was collected from the left retro-orbital sinus on study days -8, 1, 3, 7, 14, 21, 28, and 35. Serum was prepared and PK parameters were determined as described above.</p> <p>Reference: Sheridan D, et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS One. 2018 Apr 12;13(4):e0195909.</p>

美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

产品编号	品名.	Target
MB2806	aflibercept	VEGFR
MB2786	Alemtuzumab	CD52
MB2787	Alirocumab	PCSK9
MB2789	Avelumab	PDL-1
MB2790	Atezolizumab	PDL-1
MB2791	Bevacizumab	VEGF
MB2792	Cetuximab	EGFR
MB2803	Daratumumab	CD38
MB2794	Denosumab	RANK Ligand
MB2784	Adalimumab	TNF-α
MB2795	Etanercept	TNF

MB2797	Evolocumab	PCSK9
MB2773	Infliximab	TNF- α
MB2769	Ipilimumab	CTLA-4
MB2772	Matuzumab	EGFR
MB2766	Mepolizumab	IL-5
MB2767	Nivolumab	PD-1
MB2774	Obinutuzumab	CD20
MB2776	Ofatumumab	CD20
MB2777	Omalizumab	IgE
MB2781	Panitumumab	EGFR
MB2761	Pembrolizumab	PD-1
MB2762	Pertuzumab	HER2
MB2763	Ranibizumab	VEGFR
MB2938	Ramucirumab	VEGFR
MB2749	Rituximab	CD20
MB2757	Secukinumab	IL-17
MB2751	Tocilizumab/Atlizumab	IL-6 receptor
MB2753	Trastuzumab	ErbB2
MB2758	Ustekinumab	IL-12

用途及描述: 仅供科研, 严禁用于人体(For R&D Only)